1100 Boulevard Rene- Levesque Ouest
Suite 700
Montreal, QC H5B 4N4
Canada
https://www.elixxer.com
Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Ferras Zalt | Chairman & Interim CEO | 241,58k | N/D | 1963 |
Ms. Kym No C.M.A., CPA | Corporate Controller & Interim CFO | 124,11k | N/D | N/D |
Mr. Guy Charette L.L.B., LL.B. | Legal Council | N/D | N/D | 1954 |
Ms. Jeanne van Wyk | Vice President of Communications | N/D | N/D | N/D |
Mr. Daniel Lubienietzky | VP of Corporate Development | N/D | N/D | N/D |
Mr. Richard Widmann | EVP of Commercial | N/D | N/D | 1968 |
Mr. Michael Kozub | Corporate Secretary | N/D | N/D | N/D |
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.
L'ISS Governance QualityScore di Elixxer Ltd. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.